Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 09 March 2017 | By Zachary Brennan
Medical device industry group AdvaMed pointed to seven guidance documents slated for release in 2017 by the US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health as those that are of the highest priority to its member companies.
In addition to recommending that FDA finalize all of the draft guidances issued within the last year, the list of seven final guidance documents (of the 12 listed in FDA’s "A" list for 2017, meaning the agency has also prioritized them above others) include:
In terms of draft guidance, AdvaMed singles out three of the four FDA listed, including: "Update to Section V Demonstrating Insignificant Risk of an Erroneous Result in the Recommendations: Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices guidance," "Dual 510(k) and CLIA Waiver," noting the group also supports the "issuance of this guidance to support the overall dual submission process and foster efficient and effective review and waiver of these critical devices, which play an important role in providing timely and effective care for patients," and "New or revised procedural guidances for MDUFA IV implementation."
On FDA’s "B" list for final guidance, AdvaMed also points to two documents of highest priority to its members: "FDA Categorization of Investigational Device Exemption (IDE) Devices to Assist the Centers for Medicare & Medicaid Services (CMS) with Coverage Decisions" and "Unique Device Identification (UDI): Direct Marking of Devices."
For the guidance on UDIs, AdvaMed recommends "FDA move this guidance to the ‘A’ list because direct marking compliance dates for certain products began in 2016. Changes in interpretation will be costly and would create uncertainty regarding products in commercial distribution. Issuance of this guidance well in advance of the 2018 compliance date will provide manufacturers with the ability to plan and implement."
The group further calls on FDA to add two final guidance documents to its "A" list for 2017 on 510(k) modifications and software modifications.
Tags: AdvaMed, device guidance, FDA guidance 2017